| Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial. | |
| | |
MedLine Citation:
|
PMID: 19907167 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is currently the only approved acute therapy for ischemic stroke. After rt-PA-induced recanalization, reocclusion is observed in 20-34%, probably caused by platelet activation. In acute myocardial infarction, the combination of thrombolytic and antiplatelet therapy leads to a better outcome compared to thrombolytic treatment alone. In patients with acute ischemic stroke, several studies showed that those on antiplatelet treatment prior to rt-PA had an equal or even better outcome compared to patients without prior use of antiplatelet therapy, despite an increased risk of bleeding. METHODS: We present the protocol of a multicenter randomized clinical trial (n = 800) investigating the effects of immediate addition of aspirin to rt-PA on poor outcome (modified Rankin score >2) in ischemic stroke patients. CONCLUSION: This study will answer the question whether the combination of rt-PA and antiplatelet therapy improves the functional outcome in ischemic stroke patients. |
| | |
Authors:
|
S M Zinkstok; M Vermeulen; J Stam; R J de Haan; Y B Roos |
Related Documents
:
|
9161657 - Cost-effectiveness of thrombolytic therapy for acute myocardial infarction. 2584547 - Long-term benefit of early thrombolytic therapy in patients with acute myocardial infar... 8279357 - Use of composite endpoints in thrombolysis trials of acute myocardial infarction. 12528307 - Third generation thrombolytics for the treatment of ischemic stroke. 12928207 - Ventricular reshaping with devices. 1623787 - Pacemaker-induced friction rub and apical thrill. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2009-11-10 |
Journal Detail:
|
Title: Cerebrovascular diseases (Basel, Switzerland) Volume: 29 ISSN: 1421-9786 ISO Abbreviation: Cerebrovasc. Dis. Publication Date: 2010 |
Date Detail:
|
Created Date: 2009-12-09 Completed Date: 2010-02-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9100851 Medline TA: Cerebrovasc Dis Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 79-81 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. s.m.zinkstok@amc.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aspirin
/
adverse effects,
therapeutic use* Brain Ischemia / complications, drug therapy* Drug Therapy, Combination Fibrinolytic Agents / administration & dosage*, adverse effects Humans Intracranial Hemorrhages / chemically induced Netherlands Platelet Aggregation Inhibitors / adverse effects, therapeutic use* Prospective Studies Recombinant Proteins / administration & dosage Research Design* Stroke / drug therapy*, etiology Thrombolytic Therapy* / adverse effects Time Factors Tissue Plasminogen Activator / administration & dosage*, adverse effects Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Recombinant Proteins; 50-78-2/Aspirin; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Long-Term Oral Anticoagulation Therapy and the Risk of Hip Fracture in Patients with Previous Hemisp...
Next Document: D-Dimers Predict Stroke Subtype when Assessed Early.